Noked Israel’s AbbVie ABBV Stock Holding History

Noked Israel’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,900	Closed	-$211K	–	39
2019 Q2	$211K	Buy	+2,900	New	+$228K	0.26%	79

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Noked Israel's ABBV Position: Q3 2019 in Review

Noked Israel sold out of AbbVie (ABBV) in Q3 2019, closing a stake of 2,900 shares — an estimated $211K sold.

Noked Israel first reported a position in ABBV in Q2 2019 and held it in 1 quarter. The position peaked at $211K in Q2 2019. 2,002 funds tracked by Wall St. Rank hold ABBV as of Q3 2019.

Noked Israel reported no remaining AbbVie position as of Q3 2019 after selling out during the quarter.
Noked Israel sold 2,900 AbbVie shares in Q3 2019, an estimated $211K.
Noked Israel first reported a position in AbbVie in Q2 2019 and held it in 1 quarter.
Noked Israel's AbbVie position peaked at $211K in Q2 2019.
2,002 funds tracked by Wall St. Rank held AbbVie as of Q3 2019.

Based on Noked Israel's 13F filing for Q3 2019, filed 14 Nov 2019.